Kiora Pharmaceuticals Inc (KPRX) Stock Price & Analysis
Kiora Pharmaceuticals Inc (KPRX) rose 0.39% to USD 2.59 as of June 10, 2026 at 03:31 UTC, according to Nexqual real-time market data.
KPRX last closed at USD 2.58; the session ranged USD 2.52–2.67 on volume of 29,256 shares. Market capitalization is $11.48M, with a 52-week range of USD 1.77–3.34 (NCM). Source: Nexqual, June 10, 2026 at 03:31 UTC.
Key Statistics (as of June 10, 2026 at 03:31 UTC)
| Price | USD 2.59 |
|---|---|
| Change | ▲ 0.39% (up) |
| Previous Close | USD 2.58 |
| Open | USD 2.56 |
| Day Range | USD 2.52 – 2.67 |
| 52-Week Range | USD 1.77 – 3.34 |
| Volume | 29,256 shares |
| Market Cap | $11.48M |
| Exchange | NCM |
Technical Analysis (KPRX)
Nexqual's technical model rates KPRX "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:31 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.79 (neutral) |
| vs SMA50 | Above (USD 2.47) |
| MACD | 0.04 (positive) |
Analyst Ratings (KPRX)
Wall Street analysts rate KPRX "None" based on 1 analysts, with a mean price target of USD 12 (range USD 12–12), per Nexqual as of June 10, 2026 at 03:31 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 12 |
| High Target | USD 12 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (KPRX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.58 vs est -0.71 ▲ beat |
| 2025-09-30 | USD 0.01 vs est -0.72 ▲ beat |
| 2025-06-30 | USD -0.54 vs est -0.58 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financials & Fundamentals (KPRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -58.78% |
| Debt / Equity | 2.68 |
| Current Ratio | 6.68 |
| Total Cash | $13.87M |
| Total Debt | $373,586 |
| Free Cash Flow | $-9.58M |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Financial Health Score (KPRX)
Nexqual rates Kiora Pharmaceuticals Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:31 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $14M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M |
| Efficiency | Critical — ROE -59%, ROA -22.4% |
Ownership (KPRX)
| Insider Ownership | +3.05% |
|---|---|
| Institutional Ownership | +28.80% |
| Shares Outstanding | 4.43M |
| Float | 4.30M |
| Short % of Float | +0.42% |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
Leadership (KPRX)
Kiora Pharmaceuticals Inc is led by Brian M. Strem (age 45), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:31 UTC.
| President, CEO & Director | Brian M. Strem (age 45) |
|---|---|
| Chief Financial Officer | Melissa Tosca (age 45) |
| Executive Vice President of CMC & Operations | Stefan Sperl |
Major Backers & Investors (KPRX)
Notable institutional backers of Kiora Pharmaceuticals Inc include Adar1 Capital Management, LLC , Citadel, Fidelity, according to Nexqual as of June 10, 2026 at 03:31 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Adar1 Capital Management, LLC | 3.79% |
| Citadel | 1.12% |
| Fidelity | 1.04% |
| Xtx Topco Ltd | 0.33% |
| Two Sigma Securities, LLC | 0.27% |
| Rangeley Capital, LLC | 0.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.19% |
| Geode Capital | 1.08% |
Source: Nexqual, June 10, 2026 at 03:31 UTC.
From Kiora Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
- Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
- The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis.
- It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.95 | ▲ 10.24% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| ILAG | Intelligent Living Application | USD 3.73 | ▲ 6.57% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:31 UTC. This page is informational and not investment advice.